Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis

Table 2 Cost-effectiveness analysis of breast cancer screening using the multi-cohort (population level) approach

	0 % discount^a			3 % discount^a
	Mean	95 % CI		Mean	95 % CI
Screened population
Total costs (Million Euros)	1,608.7	1,566.0	1,651.7	1,126.6	1,097.8	1,155.3
Screening mammography costs	55.3	55.2	55.5	55.3	55.2	55.5
Screening diagnosis workup	12.1	11.5	12.7	12.1	11.5	12.7
Clinical cancers diagnosis workup	26.1	25.2	27.0	18.3	17.6	18.9
Treatment costs	1,515.1	1,472.8	1,557.5	1,040.9	1,012.5	1,069.3
QALYs	8,845,493	8,828,791	8,862,195	6,696,959	6,684,899	6,709,019
Unscreened population
Total costs (Million Euros)	1,584.3	1,538.8	1,629.8	1,090.2	1,059.2	1,121.3
Screening mammography costs	0.00	0.00	0.00	0.0	0.0	0.0
Screening diagnosis workup	0.00	0.00	0.00	0.0	0.0	0.0
Clinical cancers diagnosis workup	30.2	29.2	31.11	22.2	21.5	22.9
Treatment costs	1,554.1	1,509.0	1,599.24	1,068.0	1,037.3	1,098.8
QALYs	8,834,785	8,818,066	8,851,504	6,688,293	6,676,240	6,700,347
Difference (Screened - Unscreened)
Total costs (Million Euros)	24.4	8.5	40.3	36.4	24.6	1,557.5
Screening mammography costs	55.3	55.2	55.5	55.3	55.2	55.5
Screening diagnosis workup	12.1	11.5	12.7	12.1	11.5	12.7
Clinical cancers diagnosis workup	−4.0	−5.1	−2.9	−3.9	−4.8	−3.1
Treatment costs	−39.0	−54.8	−23.1	−27.1	−38.9	−15.4
QALYs	10,708	9,499	11,917	8,666	7,746	9,586
ICER	2,294	738	3,850	4,214	2,703.41	5,725

CI confidence interval, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio
^aDiscount applied beginning from the end of the evaluated period until death

ISSN: 1471-2407